Integra LifeSciences (NASDAQ:IART) Releases Q4 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its fourth quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.790-0.840 for the period, compared to the consensus EPS estimate of 0.920. The company issued revenue guidance of $420.0 million-$440.0 million, compared to the consensus revenue estimate of $456.8 million. Integra LifeSciences also updated its FY 2025 guidance to 2.190-2.240 EPS.

Integra LifeSciences Stock Performance

Shares of IART opened at $15.43 on Thursday. The company has a market capitalization of $1.20 billion, a PE ratio of -2.36 and a beta of 1.21. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. Integra LifeSciences has a one year low of $11.06 and a one year high of $27.13. The company’s fifty day moving average price is $14.80 and its 200 day moving average price is $13.87.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The company had revenue of $415.61 million during the quarter, compared to analysts’ expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The business’s quarterly revenue was down .6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.63 earnings per share. As a group, analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on IART shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Integra LifeSciences in a report on Wednesday, October 8th. Truist Financial set a $15.00 price objective on Integra LifeSciences and gave the company a “hold” rating in a research report on Wednesday, October 15th. Finally, Citigroup restated a “sell” rating and issued a $12.00 price objective (up previously from $10.00) on shares of Integra LifeSciences in a research note on Tuesday, October 7th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and an average price target of $16.17.

Institutional Trading of Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. raised its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. Orion Porfolio Solutions LLC raised its stake in shares of Integra LifeSciences by 30.8% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 41,870 shares of the life sciences company’s stock valued at $514,000 after buying an additional 9,856 shares in the last quarter. State of Wyoming raised its stake in shares of Integra LifeSciences by 84.0% in the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company’s stock valued at $159,000 after buying an additional 5,914 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Integra LifeSciences by 8.2% during the 2nd quarter. Public Sector Pension Investment Board now owns 227,821 shares of the life sciences company’s stock worth $2,795,000 after acquiring an additional 17,333 shares during the period. Finally, FORA Capital LLC acquired a new stake in shares of Integra LifeSciences during the 2nd quarter valued at about $200,000. 84.78% of the stock is currently owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.